Get the Stockscreener App
293.27
3.73%
-11.35
Beone Medicines Ltd Adr stock is traded at $293.27, with a volume of 269.68K.
It is down -3.73% in the last 24 hours and down -8.34% over the past month.
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.
See More
Previous Close:
$304.62
Open:
$299.98
24h Volume:
269.68K
Relative Volume:
1.16
Market Cap:
$30.43B
Revenue:
$5.76B
Net Income/Loss:
$514.49M
P/E Ratio:
65.44
EPS:
4.4813
Net Cash Flow:
$1.10B
1W Performance:
-6.04%
1M Performance:
-8.34%
6M Performance:
-19.83%
1Y Performance:
+29.90%
1-Day Range:
$293.09
$299.98
1-Week Range:
$293.09
$322.45
52-Week Range:
$227.05
$385.22
Beone Medicines Ltd Adr Stock (ONC) Company Profile
Name
Beone Medicines Ltd Adr
Sector
Industry
Phone
41-616851900
Address
C/O BEONE MEDICINES I GMBH, BASEL
Compare ONC vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONC
Beone Medicines Ltd Adr
|
293.27 | 31.60B | 5.76B | 514.49M | 1.10B | 4.4813 |
VRTX
Vertex Pharmaceuticals Inc
|
436.95 | 114.32B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
698.25 | 74.74B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
799.32 | 51.13B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.98 | 39.18B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
145.66 | 31.78B | 742.00K | -1.37B | -1.07B | -7.0731 |
Beone Medicines Ltd Adr Stock (ONC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | Wolfe Research | Outperform |
| Mar-16-26 | Downgrade | Jefferies | Buy → Hold |
| Nov-24-25 | Initiated | Truist | Buy |
| Sep-18-25 | Initiated | Barclays | Overweight |
| Apr-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Mar-03-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-03-24 | Resumed | Morgan Stanley | Overweight |
| Sep-18-24 | Initiated | JMP Securities | Mkt Outperform |
| Feb-06-24 | Resumed | JP Morgan | Overweight |
| Sep-12-23 | Initiated | Macquarie | Outperform |
| Aug-17-23 | Initiated | Jefferies | Buy |
| Jul-17-23 | Initiated | Citigroup | Buy |
| Jun-30-23 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-12-23 | Initiated | Daiwa Securities | Buy |
| Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-13-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Aug-09-22 | Resumed | JP Morgan | Overweight |
| Mar-17-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-07-22 | Initiated | Deutsche Bank | Buy |
| Oct-12-21 | Initiated | Bernstein | Outperform |
| Oct-06-21 | Upgrade | CLSA | Underperform → Buy |
| Mar-08-21 | Initiated | China Renaissance | Buy |
| Mar-01-21 | Downgrade | CLSA | Outperform → Underperform |
| Nov-09-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-06-20 | Downgrade | Maxim Group | Buy → Hold |
| Nov-06-20 | Downgrade | Piper Sandler | Neutral → Underweight |
View All
Beone Medicines Ltd Adr Stock (ONC) Latest News
BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma - ChartMill
Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewswire Inc.
Citi Raises BeOne Medicines Ltd. (ONC.US) TP to USD453; 1Q26 Results Strong - AASTOCKS.com
Sigma Planning Corp Sells 3,208 Shares of BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Results: BeOne Medicines AG Beat Earnings Expectations And Analysts Now Have New Forecasts - Sahm
UBS Group AG Grows Stake in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BeOne Medicines (ONC) EPS Surge Tests Bullish Profitability Narratives - Sahm
BOCI: BEONE MEDICINES 1Q Results Beat; Rating Buy Reiterated - AASTOCKS.com
G Sachs Raises BeOne Medicines Ltd. (ONC.US) TP to USD414.46, Rating Buy - AASTOCKS.com
UBS Raises BeOne Medicines Ltd. (ONC.US) TP to USD465, 1Q Results Strong - AASTOCKS.com
M Stanley Raises BeOne Medicines Ltd. (ONC.US) TP to USD395; 1Q Results Beat Expectations - AASTOCKS.com
BeOne Medicines Q1 Earnings Call Highlights - Yahoo Finance
BeOne Medicines (ONC) registers 398.9M ordinary shares for resale by major holders - Stock Titan
BEONE MEDICINES (06160.HK) 1Q Net Profit USD227 million Surges 178x YoY; Raises FY2026 Revenue Guidance - AASTOCKS.com
Is It Too Late To Consider BeOne Medicines (ONC) After Its 23% One Year Gain? - Sahm
BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Chan Henry Lee Sells 332 Shares of BeOne Medicines (NASDAQ:ONC) Stock - MarketBeat
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
RBC Capital Adjusts Price Target on BeOne Medicines to $423 From $425, Maintains Outperform Rating - Moomoo
A Look At BeOne Medicines (ONC) Valuation After New Coverage And FDA Orphan Drug Designation - Sahm
BeOne Medicines (NASDAQ:ONC) Stock Price Down 6.2%Here's Why - MarketBeat
BeOne Medicines (NASDAQ:ONC) Shares Gap Up – Here’s Why - Defense World
BeOne Medicines (NASDAQ:ONC) Shares Gap UpTime to Buy? - MarketBeat
JPMorgan Chase & Co. Sells 47,002 Shares of BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Brokerages Set BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) PT at $401.00 - Defense World
Jain Global LLC Sells 32,244 Shares of BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Chan Henry Lee Sells 341 Shares of BeOne Medicines (NASDAQ:ONC) Stock - MarketBeat
Capital International Investors Boosts Stake in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Capital International Sarl Has $50.61 Million Stake in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Capital Group Private Client Services Inc. Reduces Stock Holdings in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Pinpoint Asset Management Singapore Pte. Ltd. Has $1.49 Million Stock Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BeOne Medicines (ONC) Is Down 15.1% After Surging To GAAP Profitability And Raising 2026 GuidanceHas The Bull Case Changed? - Sahm
JPMorgan Chase & Co. Has $16.63 Million Stock Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
TD Asset Management Inc Takes $9.33 Million Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BeOne Medicines (NASDAQ:ONC) Price Target Raised to $410.00 - Defense World
Alphabet Upgraded, United Airlines Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BeOne Medicines (ONC) Reports $1.5B Revenue for Q4, $1.1B from Lymphoma Treatment - Finviz
Artisan Partners Limited Partnership Reduces Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Artisan Partners Limited Partnership Reduces Position in BeOne Medicines Ltd. – Sponsored ADR $ONC - Defense World
Generali Investments Management Co LLC Takes Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BeOne Medicines (NASDAQ:ONC) Shares Gap Down After Earnings Miss - Defense World
Here's What Important Indicators Reveal About BeOne Medicines Ltd.Sponsored ADR (ONC) Fourth Quarter Results - Bitget
Here's What Key Metrics Tell Us About BeOne Medicines Ltd.Sponsored ADR (ONC) Q4 Earnings - Yahoo Finance
BEONE MEDICINES LTD-ADR (NASDAQ:ONC) Passes Minervini's SEPA Screen with Strong Technicals and High Growth Momentum - ChartMill
Beone Medicines Ltd Adr Stock (ONC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):